ClinicalTrials.gg
Active, not recruitingNCT07021066Updated Aug 5, 2026

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

A Phase 1 interventional study of BL-M05D1 in Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by SystImmune Inc.. Active, not recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by SystImmune Inc. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 246 studies in Adenocarcinoma Of Esophagus with a site in United States — 53 open to participants now, 72 under way, 7 of them phase 3. Adenocarcinoma Of Esophagus · United States.

Planned enrollment
41st of 203
160 · median 49
Started
2025
with 9 others
Phase 1
36 of 246
12 open now
Primary completion
2027-02
later than 19 of 71 live
Registered
224th of 246
by date

Among the 246 studies in Adenocarcinoma Of Esophagus with a site in United States, this one is the 41st largest by planned enrollment of the 203 interventional ones that give a count, is one of 10 that started in 2025, is one of 36 in phase 1, reaches primary completion later than 19 of the 71 other live ones, and was the 224th registered.

Adenocarcinoma Of Esophagus

354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 81 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

53 of the 246 studies in Adenocarcinoma Of Esophagus with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Adenocarcinoma Of Esophagus with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

Read the detailed description

This is a multicenter Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetic profile, and initial efficacy of BL-M05D1 in subjects with unresectable locally advanced or metastatic solid tumors that are known to potentially express CLDN18.2, including but not limited to gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC), esophageal AC (EAC), pancreatic ductal AC (PDAC), and biliary tract cancer (BTC). Participants must have recurred or progressed on at least 1 line of prior systemic therapy (including adjuvant/neoadjuvant), have no other standard of care options, and have no available curative options.

This study will be conducted in three parts (dose escalation, dose finding and dose expansion). Subjects will be dosed on Day 1 of a continuous 21-day treatment cycle.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Advanced Pancreatic Ductal Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Biliary Tract Cancer
  • Other Solid Tumors

Keywords

  • CLDN 18.2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the form voluntarily and agreed to follow the program requirements.
  2. Age ≥18 years.
  3. of ≥3 months.
  4. Dose Escalation and Dose Finding (Parts 1 and 2): Documented locally advanced or solid tumor(s) that are known to potentially express CLDN18.2, as defined below, that have recurred or progressed on at least 1 line of prior systemic therapy (refer to Section 6.3.1), have no other standard of care options, and have no available curative options, including the following:

    1. Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AC): Participants with CLDN18.2, , , and/or microsatellite instability high (MSI-H)/mismatch repair deficiency (dMMR) positive tumors must have received targeted treatment in their .
    2. Pancreatic ductal AC (PDAC): Participants who have received at least 1 line of standard therapy.
    3. Esophageal AC (EAC): Participants with HER2, PD-L1, and/or MSI-H/dMMR positive tumors must have received targeted treatment in their prior lines of therapy.
    4. Biliary tract cancers (BTCs): Participants with HER2 overexpression, NTRK fusions, KRAS mutations, IDH1 mutations, FGFR2 fusions, BRAF mutations, and/or MSI-H/ dMMR positive tumors must have received targeted treatment in their prior lines of therapy.
    5. Other solid tumors not specified above may be included if they have documented CLDN18.2 expression by IHC (1+). As applicable per standard of care, participants with HER2 and/or PD-L1 positive tumors must have received targeted treatment in their prior lines of therapy, and participants with MSI-H or dMMR positive tumors must have received immune checkpoint inhibitor.
  5. Agree to provide most recent existing tumor samples (formalin-fixed paraffin-embedded [FFPE] tissue block or slides) from primary or metastatic sites (see details in Section 7.1.1) for tissue-based evaluation of CLDN18.2 expression. A fresh is required if no archival/FFPE block or slides are available. Re-biopsy is recommended if the participant previously received a CLDN18.2-directed treatment.
  6. At least 1 based on v1.1.
  7. Performance Status (ECOG PS) of 0 to 1.
  8. Toxicity of previous antitumor therapy has returned to Grade ≤1 as defined by the National Cancer Institute (NCI) v5.0.

    Exceptions: Alopecia and endocrinopathies controlled by replacement therapy must be Grade ≤2.

  9. No serious cardiac dysfunction, ≥50%.
  10. Adequate organ function before enrollment, defined as follows:

    1. Marrow function: (ANC) ≥1.5×109/L, (PLT) count ≥100×109/L, (Hb) ≥9.0 g/dL (blood transfusion, platelet transfusion, erythropoietin (EPO), hematopoiesis agents, and G-CSF use are not allowed 1 week prior to screening).
    2. Hepatic function: total (TBIL) ≤1.5 × (ULN) (≤3 × ULN for participants with Gilbert's syndrome or liver metastasis at baseline); (AST) and alanine aminotransferase (ALT) without liver metastasis ≤3.0 × ULN; AST and ALT with liver metastasis ≤5.0 × ULN.

      Note: For participants with Gilbert's syndrome, conjugated bilirubin ≤1.5 × ULN and TBIL \<3.0 × ULN in the absence of liver metastases.

    3. Renal function: (CrCl) ≥60 mL/min (Cockcroft-Gault equation) or estimated (eGFR) ≥50 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation).
  11. Coagulation parameters: (INR) ≤1.5 × ULN, and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless receiving anticoagulation therapy with prothrombin time and aPTT levels within the intended therapeutic range.
  12. Sexually active fertile participants and their partners must agree to use highly effective methods of (defined in Section 17.5 [Appendix E]) during the course of the study and after the last dose of study treatment (7 months for women and 4 months for men). An additional contraceptive method, such as a barrier method (eg, condom), is recommended.
  13. Individuals of (IOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female participants are considered IOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented status (defined as 12 months of amenorrhea in a woman >45 years old in the absence of other biological or physiological causes). In addition, females \<55 years old must have a serum follicle-stimulating hormone (FSH) level >40 mIU/mL to confirm menopause.

    Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.

  14. All participants must be willing to receive prophylactic G-CSF during their time on study (see Section 6.3.4.5).

    Additional Inclusion Criteria for Dose Optimization (Part 3)

  15. PDAC Expansion Arm: Participants who have received at least 1 line of standard therapy and no more than 2 lines of systemic therapy (refer to Section 6.3.1).

    Note: Participants who have received prior treatment with a CLDN18.2-directed treatment must be able and willing to provide tissue sample obtained following treatment with anti-CLDN18.2 agent.

  16. Basket Expansion Arm: Documented locally advanced or metastatic solid tumor(s) that are known to potentially express CLDN18.2 as defined below that have recurred or progressed on at least 1 line of prior systemic therapy in the advanced or metastatic setting (refer to Section 6.3.1).

    1. G/GEJ AC: Participants with CLDN18.2, HER2, PD-L1, and/or MSI-H/dMMR positive tumors must have received targeted treatment in their prior lines of therapy.
    2. G/GEJ AC and BTCs: Participants who have received prior treatment with an anti-CLDN18.2 antibody must be able and willing to provide tissue sample obtained following treatment with anti-CLDN18.2 agent.
    3. BTCs: Participants with HER2 overexpression, NTRK fusions, KRAS mutations, IDH1 mutations, FGFR2 fusions, BRAF mutations, and/or MSI-H/dMMR positive tumors must have received targeted treatment in their prior lines of therapy.

Exclusion criteria

Exclusion Criteria:

  1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small-molecule inhibitor of tyrosine kinase), or other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration of study drug; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration.
  2. Participants with history of severe heart disease such as symptomatic congestive heart failure (CHF) Grade ≥2 ( v5.0), (NYHA) Grade ≥2 heart failure at any time, or history of myocardial infarction or unstable angina pectoris within 6 months before enrollment.
  3. Participants with prolonged corrected (QTcF) >470 msec, complete left bundle branch block, Grade 3 atrioventricular block.
  4. Active diseases and inflammatory diseases such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease, or Hashimoto's thyroiditis..

    Exception: Participants with skin diseases that do not require systemic treatment (such as vitiligo, psoriasis); well-controlled type 1 diabetes; or hypothyroidism are permitted.

    Note: For autoimmune conditions that are active but stable, low grade, and on systemic therapy, discussion with the medical monitor is required prior to screening.

  5. Participants with other prior .

    Exceptions: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years prior to screening.

  6. Participants with advanced or lung diseases such as poorly controlled (COPD) or asthma, restrictive lung disease, or pulmonary hypertension.
  7. Participants who have a history of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with or have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  8. Participants with stroke or (TIA) within 6 months before enrollment.
  9. Participants with a thromboembolic event (eg, deep vein thrombosis, pulmonary embolism) within 6 months before enrollment.

    Exception: Those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before enrollment may participate.

  10. Participants with primary tumors in the central nervous system (CNS), or active or untreated and/or carcinomatous meningitis.

    Exception: Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks, have no evidence of new or enlarging brain metastases, and have no requirements for corticosteroids 14 days prior to dosing with the IP. Participants on low-dose corticosteroids (\<10 mg prednisone or equivalent/day) may participate.

  11. Participants with pre-existing Grade ≥2 peripheral neuropathy.
  12. Participants who have a history of anaphylaxis or severe to recombinant humanized antibodies, human-mouse chimeric antibodies, or any of the components of BL-M05D1.
  13. Participants who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone.

    Exceptions:

    1. Treatment of COPD and infusion-related reactions (IRRs) is permitted.
    2. Treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone), including antiemetics, is permitted.
    3. The chronic use of topical, inhaled, and locally injected steroids is permitted.
  14. Participants with known or suspected (HIV) infection (HIV antibody positive).

    Exceptions: Participants are allowed to participate if all the following criteria are met:

    1. undetectable HIV RNA and ≥350 cells/μL at screening;
    2. no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 12 months prior to screening; and
    3. on stable antiretroviral therapy (ART) for at least 4 weeks prior to enrollment, with projected continuation of ART as clinically indicated while on the study.
  15. Participants with known active virus (HBV) infection (positive hepatitis B surface antigen [HBsAg] test).

    Exceptions: Participants with a chronic inactive HBV infection are eligible if all the following criteria are met:

    1. HBV DNA viral load \<500 IU/mL;
    2. normal and ALT, or if liver is present, AST and ALT \<3 × that are not attributed to HBV infection; and
    3. on antiviral treatment as clinically indicated.
  16. Participants with known active virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection).

    Exception: Participants with a positive anti-HCV antibody are eligible only if quantitative polymerase chain reaction (qPCR) is negative for HCV-RNA.

  17. Participants with known active tuberculosis.
  18. Participants with active infections that require IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, or sepsis, within 1 week prior to first dose of study treatment.

    Exception: Participants on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible.

  19. Participants who are pregnant, breastfeeding, or planning to become pregnant during the study.
  20. Other conditions that the investigator or sponsor believes are not suitable for participating in this clinical trial.
  21. For Dose Optimization Only: Prior treatment with any topoisomerase inhibitor ADC.
Terms in these criteria, in plain language(38)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Experimental BL-M05D1 administered Day 1 per cycle

    BL-M05D1 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks

    Drug: BL-M05D1

Interventions

  • BL-M05D1 will be administered on D1 every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Participants with Dose-limiting toxicities

    A DLT is defined as the following: Toxicity that results in a \>14-day delay in treatment \- Hematologic toxicities Grade 4 neutrophil count decreased lasting \>7 days Grade ≥3 febrile neutropenia of any duration Grade ≥3 platelet count decreased with clinically significant hemorrhage Grade 4 thrombocytopenia lasting \>72 hours \- Nonhematologic toxicities Death not clearly related to disease progression or extraneous cause Hy's law cases Grade ≥3 nonhematologic toxicities, except for: Grade 3 nausea/vomiting or diarrhea for less than 72 hours with adequate antiemetic and other supportive care Grade 3 fatigue for less than 1 week Grade ≥3 electrolyte abnormality that lasts up to 72 hours, is not clinically complicated, and resolves spontaneously or responds to conventional medical interventions Grade ≥3 amylase or lipase that is not associated with symptoms or clinical manifestations of pancreatitis

    Time frame: 1 year

  2. Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)

    Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)

    Time frame: 1 year

  3. Participants with abnormal physical examination findings

    Measure the number of participants with abnormal physical examination findings.

    Time frame: 1 year

  4. Participants with ability to care for themselves, daily activity, and physical activity

    Measure the change in participants with Eastern Clinical Oncology Group (ECOG) Scale of Performance Status. The scale is 0-4 with 0 being the fully active (best outcome) and 4 being completely disabled (worst outcome)

    Time frame: 1 year

  5. Participants with abnormal ECG and ECHO/MUGA reading

    Patients with abnormal ECG parameters (including the change from-baseline ECG parameters: heart rate \[HR\]; PR; QTcF; and QRS intervals \[∆HR, ∆PR, ∆QTcF, and ∆QRS\]), and ECHO/MUGA findings

    Time frame: 1 year

  6. Participants with abnormal lab results

    Measure the number of participants with abnormal clinical laboratory values

    Time frame: 1 year

  7. To determine the maximum tolerated dose (MTD) if reached or minimum safe and pharmacologically effective dose (MSED).

    The actual number of subjects enrolled and dose levels to be explored in this study will depend on the MTD and/or MSED based on DLTs reported during the DLT observation period.

    Time frame: 1 year

Secondary outcomes

  1. Cmax of BL-M05D1

    Calculate maximum (peak) observed concentration of BL-M05D1

    Time frame: 1 year

  2. Cmax of anti-BL-M05D1 antibodies

    Calculate maximum (peak) observed concentration of anti-BL-M05D1 antibodies

    Time frame: 1 year

  3. Cmax of free payload ED-04

    Calculate maximum (peak) observed concentration of free payload ED-04

    Time frame: 1 year

  4. Tmax of BL-M05D1

    Calculate time of maximum observed concentration of BL-M05D1

    Time frame: 1 year

  5. Tmax of anti-BL-M05D1 antibodies

    Calculate time of maximum observed concentration of anti-BL-M05D1 antibodies

    Time frame: 1 year

  6. Tmax of free payload ED-04

    Calculate time of maximum observed concentration of free payload ED-04

    Time frame: 1 year

  7. AUC(0-8) of BL-M05D1

    Calculate area under the serum concentration-time curve of BL-M05D1 from time 0 to 8 hours

    Time frame: 1 year

  8. AUC(0-8) of anti-BL-M05D1 antibodies

    Calculate area under the serum concentration-time curve of anti-BL-M05D1 antibodies from time 0 to 8 hours

    Time frame: 1 year

  9. AUC(0-8) of free payload ED-04

    Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours

    Time frame: 1 year

  10. AUC(last) of BL-M05D1

    Calculate area under the serum concentration-time curve up of BL-M05D1 to the last quantifiable time0 to 8 hours

    Time frame: 1 year

  11. AUC(last) of anti-BL-M05D1 antibodies

    Calculate area under the serum concentration-time curve up of anti-BL-M05D1 antibodies to the last quantifiable time0 to 8 hours

    Time frame: 1 year

  12. AUC(last) of free payload ED-04

    Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time

    Time frame: 1 year

  13. Overall Response Rate (ORR)

    To assess the clinical efficacy of BL-M05D1 as measured by ORR using RECIST criteria v 1.1

    Time frame: 1 year

  14. Disease Control Rate (DCR)

    To assess the clinical efficacy of BL-M05D1 as measured by DCR using RECIST criteria v 1.1

    Time frame: 1 year

  15. Time To Response (TTR)

    To assess the clinical efficacy of BL-M05D1 as measured by TTR using RECIST criteria v 1.1

    Time frame: 1 year

  16. Progression-Free Survival (PFS)

    To assess the clinical efficacy of BL-M05D1 as measured by PFS using RECIST criteria v 1.1

    Time frame: 1 year

  17. Overall Survival (OS)

    To assess the clinical efficacy of BL-M05D1 as measured by OS using RECIST criteria v 1.1

    Time frame: 1 year

  18. Duration of response (DoR)

    To assess the clinical efficacy of BL-M05D1 as measured by DoR using RECIST criteria v 1.1

    Time frame: 1 year

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 13, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
May 31, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021066
Lead sponsor
SystImmune Inc.
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jul 30, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Sarah Tannenbaum
study director · SystImmune Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1

Start the discussion